{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000177","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.371613+00:00","generated_at":"2026-05-30T00:59:10.347595+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis appoints Julie Eastland CEO, succeeding Blackwell; plans registrational studies for azenosertib","bullets":["Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.","Ingmar Bruns appointed Chief Medical Officer; Scott Myers appointed Board Chairperson.","Cam Gallagher resigned as President/Interim CFO; Vincent Vultaggio named interim principal financial officer.","Board approved amendment to 2022 Inducement Plan, increasing available shares by 5,500,000.","Company plans to host investor event in Jan 2025 with updated azenosertib data and regulatory update."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000177","json":"https://secwatch.observer/filing/0001725160-24-000177.json","markdown":"https://secwatch.observer/filing/0001725160-24-000177.md","text":"https://secwatch.observer/filing/0001725160-24-000177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/zntl-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:59:10.347595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a8ab3f2b3","claim":"Julie Eastland was appointed as Chief Executive Officer, President and a Class I director at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"On November 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Julie Eastland as Chief Executive Officer, President and a Class I director of the Company with an initial term scheduled to expire at the Company’s 2027 Annual Meeting of Stockholders, in each case effective November 13, 2024 (the “Transition Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, President and a Class I director"}],"fact_type":"executive_change"},{"claim_id":"c8342a897f","claim":"Kimberly Blackwell resigned as Chief Executive Officer and Director at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"Also on November 12, 2024, Kimberly Blackwell, M.D., resigned as Chief Executive Officer, a member of the Board and from all other positions held with the Company and its affiliates, effective on the Transition Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}